Jefferies Maintains Buy on Apellis Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari maintains a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a price target of $80.
July 31, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Akash Tewari maintains a Buy rating on Apellis Pharmaceuticals with a price target of $80.
The reaffirmation of a Buy rating and a price target of $80 by Jefferies is likely to positively impact Apellis Pharmaceuticals' stock price in the short term as it reinforces investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100